Clinical trial NCT04882371 - References

Breast Cancer — Comparison of MRI With PET / CT in the Evaluation of Response to Neoadjuvant Therapy Based on the Molecular Subtypes of Breast Cancer

Citation(s)

•   Abedi M, Farrokh D, Shandiz Homaei F, Joulaee A, Anbiaee R, Zandi B, Gity M, Sayah HR, Abedi MS
  The validity of MRI in evaluation of tumor response to neoadjuvant chemotherapy in locally advanced breast cancer. Iran J Cancer Prev. 2013 Winter;6(1):28-35.
•   An YY, Kim SH, Kang BJ, Lee AW
  Treatment Response Evaluation of Breast Cancer after Neoadjuvant Chemotherapy and Usefulness of the Imaging Parameters of MRI and PET/CT. J Korean Med Sci. 2015 Jun;30(6):808-15. doi: 10.3346/jkms.2015.30.6.808. Epub 2015 May 13. Erratum in: J Korean Med Sci. 2015 Dec;30(12):1924.
•   Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, Schnall M, Alavi A
  Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer. 2008 Mar 1;112(5):995-1000.
•   Boughey JC, McCall LM, Ballman KV, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Leitch AM, Flippo-Morton T, Hunt KK
  Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. Ann Surg. 2014 Oct;260(4):608-14; discussion 614-6. doi: 10.1097/SLA.0000000000000924.
•   Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordström EB, Pagani O, Partridge A, Penault-Llorca F, Piccart MJ, Rugo H, Sledge G, Thomssen C, Van't Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer E; European School of Oncology; European Society of Medical Oncology
  ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast. 2014 Oct;23(5):489-502. doi: 10.1016/j.breast.2014.08.009. Epub 2014 Sep 20.
•   Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE Jr, Pazdur R, Ditsch N, Rastogi P, Eiermann W, von Minckwitz G
  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014 Jul 12;384(9938):164-72. doi: 10.1016/S0140-6736(13)62422-8. Epub 2014 Feb 14. Review. Erratum in: Lancet. 2019 Mar 9;393(10175):986.
•   Dhillon GS, Bell N, Ginat DT, Levit A, Destounis S, O'Connell A
  Breast MR Imaging: What the Radiologist Needs to Know. J Clin Imaging Sci. 2011;1:48. doi: 10.4103/2156-7514.85655. Epub 2011 Oct 3.
•   Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, Zambetti M, Moliterni A, Vazquez F, Byakhov MJ, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Magazzù D, Heinzmann D, Steinseifer J, Valagussa P, Baselga J
  Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol. 2014 May;15(6):640-7. doi: 10.1016/S1470-2045(14)70080-4. Epub 2014 Mar 20. Erratum in: Lancet Oncol. 2018 Dec;19(12):e667.
•   Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN
  Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol. 2007;608:1-22. Review.
•   Han S, Choi JY
  Prognostic value of (18)F-FDG PET and PET/CT for assessment of treatment response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. Breast Cancer Res. 2020 Oct 31;22(1):119. doi: 10.1186/s13058-020-01350-2.
•   Hegarty C, Collins CD
  PET/CT and breast cancer. Cancer Imaging. 2010 Oct 4;10 Spec no A:S59-62. doi: 10.1102/1470-7330.2010.9031. Review.
•   International Agency for Research on Cancer, Globocan 2018 Report
  https://www.uicc.org/news/global-cancer-data-globocan-2018
•   Jones EF, Hathi DK, Freimanis R, Mukhtar RA, Chien AJ, Esserman LJ, Van't Veer LJ, Joe BN, Hylton NM
  Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy. Cancers (Basel). 2020 Jun 9;12(6). pii: E1511. doi: 10.3390/cancers12061511. Review.
•   Kim TH, Kang DK, Yim H, Jung YS, Kim KS, Kang SY
  Magnetic resonance imaging patterns of tumor regression after neoadjuvant chemotherapy in breast cancer patients: correlation with pathological response grading system based on tumor cellularity. J Comput Assist Tomogr. 2012 Mar-Apr;36(2):200-6. doi: 10.1097/RCT.0b013e318246abf3.
•   Landis JR, Koch GG
  The measurement of observer agreement for categorical data. Biometrics. 1977 Mar;33(1):159-74.
•   Mauri D, Pavlidis N, Ioannidis JP
  Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005 Feb 2;97(3):188-94.
•   Nunes LW, Schnall MD, Orel SG, Hochman MG, Langlotz CP, Reynolds CA, Torosian MH
  Correlation of lesion appearance and histologic findings for the nodes of a breast MR imaging interpretation model. Radiographics. 1999 Jan-Feb;19(1):79-92.
•   Park SH, Moon WK, Cho N, Chang JM, Im SA, Park IA, Kang KW, Han W, Noh DY
  Comparison of diffusion-weighted MR imaging and FDG PET/CT to predict pathological complete response to neoadjuvant chemotherapy in patients with breast cancer. Eur Radiol. 2012 Jan;22(1):18-25. doi: 10.1007/s00330-011-2236-x. Epub 2011 Aug 16.
•   Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, Margolese RG, Hoehn JL, Vogel VG, Dakhil SR, Tamkus D, King KM, Pajon ER, Wright MJ, Robert J, Paik S, Mamounas EP, Wolmark N
  Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008 Feb 10;26(5):778-85. doi: 10.1200/JCO.2007.15.0235. Erratum in: J Clin Oncol. 2008 Jun 1;26(16):2793.
•   Rausch DR, Hendrick RE
  How to optimize clinical breast MR imaging practices and techniques on Your 1.5-T system. Radiographics. 2006 Sep-Oct;26(5):1469-84. Review.
•   Resende U, Cabello C, Oliveira Botelho Ramalho S, Zeferino LC
  Predictors of Pathological Complete Response in Women with Clinical Complete Response to Neoadjuvant Chemotherapy in Breast Carcinoma. Oncology. 2018;95(4):229-238. doi: 10.1159/000489785. Epub 2018 Jul 19.
•   Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L
  Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005 Aug 15;11(16):5678-85.
•   Spring LM, Fell G, Arfe A, Sharma C, Greenup R, Reynolds KL, Smith BL, Alexander B, Moy B, Isakoff SJ, Parmigiani G, Trippa L, Bardia A
  Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. Clin Cancer Res. 2020 Jun 15;26(12):2838-2848. doi: 10.1158/1078-0432.CCR-19-3492. Epub 2020 Feb 11.
•   Tang S, Xiang C, Yang Q
  The diagnostic performance of CESM and CE-MRI in evaluating the pathological response to neoadjuvant therapy in breast cancer: a systematic review and meta-analysis. Br J Radiol. 2020 Aug;93(1112):20200301. doi: 10.1259/bjr.20200301. Epub 2020 Jul 2.
•   Tateishi U, Miyake M, Nagaoka T, Terauchi T, Kubota K, Kinoshita T, Daisaki H, Macapinlac HA
  Neoadjuvant chemotherapy in breast cancer: prediction of pathologic response with PET/CT and dynamic contrast-enhanced MR imaging--prospective assessment. Radiology. 2012 Apr;263(1):53-63. doi: 10.1148/radiol.12111177.
•   Tozaki M, Kobayashi T, Uno S, Aiba K, Takeyama H, Shioya H, Tabei I, Toriumi Y, Suzuki M, Fukuda K
  Breast-conserving surgery after chemotherapy: value of MDCT for determining tumor distribution and shrinkage pattern. AJR Am J Roentgenol. 2006 Feb;186(2):431-9.
•   Wang H, Mao X
  Evaluation of the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer. Drug Des Devel Ther. 2020 Jun 18;14:2423-2433. doi: 10.2147/DDDT.S253961. eCollection 2020. Review.
•   Wang Y, Zhang C, Liu J, Huang G
  Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis. Breast Cancer Res Treat. 2012 Jan;131(2):357-69. doi: 10.1007/s10549-011-1780-z. Epub 2011 Sep 30.
•   World Health Organization, Fact Sheets, Detail, Cancer
  https://www.who.int/news-room/fact-sheets/detail/cancer

Comparison of MRI With PET / CT in the Evaluation of Response to Neoadjuvant Therapy Based on the Molecular Subtypes of Breast Cancer

Details for clinical trial NCT04882371